?? We're thrilled to announce that the FDA has confirmed the acceptability of our remaining Phase 3 trials for PL9643, following previous trials that showed strong safety, tolerability, and statistically significant symptom relief. This milestone brings us closer to offering a new therapeutic option for millions affected by Dry Eye Disease. Explore the details and what this means for the future of eye care:?https://lnkd.in/gXnnB2XC #DryEyeDisease #FDA #ClinicalTrials #Biotechnology #PalatinTechnologies #EyeCare
Palatin Technologies
制药业
We discover and develop novel therapeutics for patients living with inflammatory and autoimmune conditions.
关于我们
Palatin (NYSE American: PTN) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system. The melanocortin system is involved in regulating important physiological activities such as food intake and energy balance, desire and arousal, and the resolution of harmful inflammation. We are the first company to obtain FDA approval for a melanocortin based therapeutic, Vyleesi?, a treatment for women with hypoactive sexual desire disorder (HSDD). With the successful development of Vyleesi? and our extensive experience in the development of melanocortin based therapeutics, we are now focused on developing therapeutics that take advantage of the key role that the melanocortin system plays in the resolution of harmful inflammation. This has the potential to treat diseases that affect the eye, gastrointestinal system and the kidney. Our most advanced ocular product is PL9643, a topical treatment for dry eye disease, which is targeted to enter Phase 3 clinical trials in 2H 2021. We also have therapeutics in earlier stages of development for ophthalmic indications such as non-infectious uveitis, retinopathies and corneal diseases. Therapeutics that modulate the activity of the melanocortin system will have broad utility and to establish this, we are planning to conduct proof of concept clinical studies in ulcerative colitis and kidney disease. Vyleesi? is the first and only on-demand, FDA-approved treatment for premenopausal women suffering with HSDD, which affects 1 in 10 pre-menopausal women. Learn about this condition here: https://www.unblush.com/ To learn more about Vyleesi?, including Important Safety Information, visit here: https://www.vyleesi.com/ We are very excited by the tremendous potential our therapeutics have to positively impact the lives of patients and the value we can build for our shareholders. Find more information about our programs: www.palatin.com
- 网站
-
https://www.palatin.com/
Palatin Technologies的外部链接
- 所属行业
- 制药业
- 规模
- 51-200 人
- 类型
- 上市公司
地点
Palatin Technologies员工
动态
-
?? Major Milestone in Obesity Treatment ?? Palatin has dosed the first patient in its Phase 2 clinical study, combining Bremelanotide with Tirzepatide (GLP-1) for obesity treatment. This groundbreaking study could open doors to a future where obesity treatment is more personalized and effective. With enrollment expected to be completed in 3Q 2024 and topline results coming in 1Q 2025, the future looks promising for weight loss solutions. Data shows that 67% of patients on the popular obesity drugs discontinue use in the first year, often resulting in a rebound effect with patients gaining back most of the weight they lost. Our research indicates that combining an MCR4 agonist with a GLP-1 therapeutic may result in synergistic effects on weight loss at lower and better tolerated doses. Learn more about how we’re advancing treatments that harness the power of the melanocortin system to unlock new therapeutic possibilities. https://lnkd.in/gc8uuHfw #Biotech #Pharma #ObesityTreatment #ClinicalTrials #InvestmentOpportunity #HealthcareInnovation
First Patient Dosed in Phase 2 Clinical Study of Palatin’s Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
https://palatin.com
-
??More Exciting News from Palatin Technologies! ?? We're thrilled to announce positive results from our Phase 3 PL9643 MELODY-1 clinical trial for Dry Eye Disease, showcased at the ASCRS 2024. ?? Key Highlights: ?? The co-primary symptom endpoint of pain met statistical significance. ??Rapid onset of efficacy was observed within just two weeks. ??Outstanding safety and tolerability profile. These results underscore PL9643's potential in transforming DED treatment and position us at the forefront of ophthalmic innovation. ?? Dive into the full details of our positive phase 3 results here. https://lnkd.in/g3QA4TBF
-